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Human parvovirus 4 has been considered to be trans-
mitted only parenterally. However, after novel genotype 3 
of parvovirus 4 was found in 2 patients with no parenteral 
risks, we tested infants in Ghana. A viremia rate of 8.6% over 
2 years indicates that this infection is common in children 
in Africa.
I
n 2005, a novel human parvovirus, termed parvovirus 4 
(PARV4), was identiﬁ  ed in a plasma sample from a pa-
tient with symptoms resembling those of acute HIV infec-
tion (1). In 2006, a related virus was discovered in plasma 
pools for manufacture of plasma-derived medical products; 
the virus was initially called PARV5 and is now called 
PARV4 genotype 2 (2). Phylogenetic analysis suggested 
that PARV4 formed a separate novel genus within the sub-
family Parvovirinae.
Initial PCR analyses of blood and autopsy specimens 
from adults suggested that PARV4 infection was restricted 
to persons at risk of parenteral infection with viruses such 
as hepatitis C virus (HCV) or HIV (e.g., injection drug 
users) (3–5). A recent serologic study identiﬁ  ed high fre-
quencies of immunoglobulin G against PARV4 in injection 
drug users who were co-infected with HCV and HIV and 
in persons with hemophilia who had been exposed to non–
virus-inactivated clotting factor concentrates (6). Absence 
of serologic reactivity in adults without parenteral risk fac-
tors supported an association between PARV4 and blood-
borne transmission.
Only limited genetic diversity has been found among 
PARV4 sequences, particularly among genotype 1 viruses, 
suggesting recent emergence and spread among parenter-
ally exposed persons in Europe and the United States (5). 
Because persons with PARV4 genotype 1 DNA in their 
tissues have been substantially younger than those with 
genotype 2, a recent shift in prevalence of the 2 genotypes 
has been suggested; genotype 1 currently predominates (4). 
An even more pronounced shift was found for parvovirus 
B19 in that nearly complete cessation of genotype 2 and 
replacement by genotype 1 occurred in the 1960s in west-
ern countries (7). Furthermore, molecular clock analysis 
indicated that B19 genotype 3, which is endemic to West 
Africa and rarely detected outside Africa, may be more an-
cient than genotypes 1 and 2 (8).
Recently, a novel PARV4 variant, termed genotype 3, 
was identiﬁ  ed in tissue samples of 2 adults from Nigeria 
and the Democratic Republic of the Congo (9). Each pa-
tient had signs of AIDS but was antibody negative for HCV 
and had no evidence of parenteral exposure. The absence of 
parenteral risks raises the possibility of alternative routes of 
transmission that might affect the general, nonparenterally 
exposed, population (9). Proving nonparenteral transmis-
sion would suggest more widespread distribution of PARV4 
in humans than previously expected and occurrence of vi-
rus in additional population subsets. We therefore studied 
the occurrence of PARV4 in infants in Ghana.
The Study
We analyzed 279 anonymous blood samples that had 
been collected during a trial of intermittent preventive 
malaria treatment for infants from January 2004 through 
September 2005 (10). Samples came from infants from 9 
villages in the rural Aﬁ  gya Sekyere district, Ashanti re-
gion, Ghana, where estimated prevalences of HIV-1 and 
HCV in adults were <3% (10) and 2.5% (11), respective-
ly. For storage under tropical conditions, an equal volume 
of whole blood in EDTA was supplemented with buffer 
AS1 (QIAGEN, Hilden, Germany). DNA isolation was 
conducted on a BioRobot M48 workstation (QIAGEN), 
using the MagAttract M48 DNA Mini Kit (QIAGEN) 
as recommended (sample input volume 200 μL, elution 
volume 200 μL).
All samples were ﬁ   rst tested by a previously de-
scribed real-time PCR designed to detect established 
PARV4 genotypes 1 and 2 (12). When initial sequencing 
identiﬁ  ed novel PARV4 genotype 3, a speciﬁ  c real-time 
PCR for this genotype was developed by using prim-
ers 5′-ACCAAGGACACCAGACAGTCTT-3′ and 5′-
ACGTGTTCAGACCAAAAGGAT-3′ and probe 5′-FAM-
CCAGCTCCATACCTTTCAGCAGTTGC-BHQ1-3′. All 
samples were retested by using a plasmid-based standard 
derived from the real-time PCR amplicon of sample Gha-
na19 for absolute quantiﬁ  cation of genome copy numbers. 
The lower limit of detection of this assay was 10 plasmid 
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Freiburg, Germany.copies/reaction. Procedures to prevent PCR contamination 
were strictly adhered to, and negative controls were used 
throughout.
In total, 24 (8.6%) of 279 samples were positive for 
PARV4 genotype 3 DNA. At the time of blood collection, 
no infant had signs of acute infection (fever, rash, my-
algia). Positive samples were found for infants in 7 of 9 
studied villages, indicating widespread prevalence. To test 
whether socioeconomic factors might inﬂ  uence prevalence, 
we conducted a χ2 test. A signiﬁ  cantly lower relative risk 
of acquiring PARV4 infection was found for children who 
had access to a kitchen (indicative of higher level of hy-
giene within household) and who did not live close to a 
river (Table).
Two age groups were randomly selected from the co-
hort: 1) 94 infants with a median age of 14.9 months (in-
terquartile range 14.5–15.5 months; 47 male, 47 female) 
and 2) 185 infants with a median age of 24.0 months (in-
terquartile range 23.5–24.2 months; 92 male, 93 female). 
Signiﬁ  cantly more positive results were seen among infants 
in the older versus the younger age group (22/185 [11.9%] 
vs. 2/94 [2.1%], respectively; p<0.006). Viral loads in the 
whole study group ranged from 420 to 56,000 copies/mL of 
whole blood (median 3,400 copies/mL). Median viral loads 
did not differ signiﬁ  cantly between the age groups (4,300 
vs. 3,200 copies/mL).
A 746-nt fragment of open reading frame (ORF) 1 and 
a 558-nt fragment of the ORF2 gene and the noncoding 
region between them were sequenced. Maximal nucleotide 
distances from previously known PARV4 sequences were 
7%–8%. To obtain highly informative sequence datasets 
for phylogenetic analysis, we concatenated ORF1 and 2 se-
quences and excluded interfragment recombination by us-
ing SimPlot and GARD analysis with the HYPHY package 
(13). We then conducted phylogenetic analysis on the con-
catenated fragments by using the neighbor-joining meth-
od (Figure). The novel viruses from Ghana clustered in a 
monophyletic clade with the Nigerian PARV4 genotype 3 
prototype strain NG-OR. Within this clade, sequences 1, 3, 
4, 10, 12, 13, 17, 18, 19, 20, 21, 23, and 24, sampled from 
the 2 neighboring villages Asamang and Kona, formed a 
separate monophyletic subclade, suggesting local epidemic 
transmission of a unique virus lineage.
Conclusions
Although infection with human parvovirus PARV4 
has been considered to be restricted to adults and trans-
mitted parenterally, we found high prevalence of PARV4 
genotype 3 in blood of infants in Africa. In agreement with 
ﬁ  ndings for the 2 adults with PARV4 genotype 3 infection 
(9), clinical signs in these children were not overt. PARV4 
infection might thus be clinically silent, or acute infection 
might be followed by low-level viremia that is cleared 
slowly, similar to infection with B19.
Finding PARV4 genotype 3 over a 2-year period in 
several villages suggests common and ubiquitous preva-
lence. Parenteral medical treatment could be clearly ruled 
out as a transmission route for the viremic children >2 
months of age because these children were under medical 
observation. It could not be ruled out for younger children; 
however, because such treatment is uncommon in the rural 
Ashanti region, it is unlikely. The possibility of virus trans-
mission by vaccination with inadequately sterilized needles 
is excluded because vaccination was conducted with single-
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Table. Socioeconomic risk factors associated with PARV4 genotype 3 in whole blood from infants, Ghana, January 2004–September 
2005*
Factor† No. tested‡ 
PARV4 viremia until month 24 
No. (%) positive  RR (95% CI)  p value§
Kitchen available 
 No  137 15 (11.0)  1
 Yes  126 5 (4.0)  0.36 (0.14–0.97)  0.033
 Data  lacking  16 
River close 
 No  197 13 (6.6)  1
 Yes  69 10 (14.5)  2.2 (1.01–4.78)  0.045
 Data  lacking  13
Water source 
 Pipe  164 10 (6.1)  1
  Pump, well, or borehole  88 10 (11.4)  1.86 (0.81–4.31)  0.140
 Other  14 2 (14.3)  2.34 (0.57–9.66)  0.241
 Data  lacking  13
*PARV4, parvovirus 4; RR, relative risk; CI, confidence interval.  
†Other socioeconomic factors recorded, all without association with PARV4 genotype 3 viremia, were occupation of mother, education of mother, 
occupation of father, education of father, number of pregnancies, age of mother, age of father, no. children in household, no. adults in household, house 
type, no. rooms in house, financial situation, knowledge of malaria protection, mosquito protection, electricity in household, availability of radio or 
television.  
‡Socioeconomic interviews could not be conducted for 11 participants, and 5 questionnaires were incomplete. 
§F
2 test. PARV4 Genotype 3 in Infants, Ghana
used syringes. Finding virus in persons without parenteral 
exposure overlaps with a recently raised suspicion regard-
ing a different epidemiology of PARV4 infection in Africa 
as opposed to the Northern Hemisphere (9).
High prevalence in children in Africa contrasts with 
the prevalence pattern in the Northern Hemisphere, sug-
gesting different dynamics and routes of transmission. Pre-
natal or perinatal transient infection can be largely ruled out 
because the older children had substantially higher rates of 
viremia. On the contrary, our analysis of socioeconomic 
factors identiﬁ  ed a reciprocal association of transmission 
risk with access to a kitchen and distance from a river. 
Foodborne or smear transmission (contact with contami-
nated objects) are thus suspected. In conclusion, in Africa, 
novel PARV4 genotype 3 is prevalent among infants who 
are most likely not at risk for parenteral exposure.
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